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Tumor cells lacking the functional p53 suppressor gene may
arrest at the G2 phase of the cell cycle after exposure to ionizing
radiation, resulting in increased radioresistance. Methylxan-
thines (MTXs), such as pentoxifylline (PTX) or caffeine (CAF), can
inhibit the G2-phase checkpoint arrest of damaged cells and
thus radiosensitize them. However, the effect of MTX in cells
irradiated with low-dose-rate b-emission is not well understood.
Methods: A clonogenic assay was performed with LS180 hu-
man colon cancer cells lacking the functional p53 suppressor
gene. Cells were irradiated with increasing concentrations of
186Re-mercaptoacetyltriglycine (186Re-MAG3)-labeled A7 mono-
clonal antibody against colorectal cancer (0–925 kBq/mL) at
37°C in 5% CO2 for 24 h in the presence or absence of PTX (0–2
mmol/L) or CAF (0–5 mmol/L). The enhancement ratio (ER) with
MTX was calculated as a ratio of 50% cell-killing concentration
of 186Re-MAG3-A7 in control cells to that in cells treated with
PTX or CAF. The cell cycle distribution was analyzed with a flow
cytometer. Results: The concentration of 50% cell kill was 474
kBq/mL 186Re-MAG3-A7. Both PTX and CAF dose dependently
enhanced the cytotoxicity of 186Re-MAG3-A7: ERs of 0.5
mmol/L PTX, 2 mmol/L PTX, 1 mmol/L CAF, and 5 mmol/L CAF
were 1.50, 2.18, 1.54, and 2.63, respectively. Flow cytometry
showed that the percentage nonirradiated cells in the G2/M
phase of the cell cycle was 11.3% 6 1.66%. On the other hand,
cells exposed to 186Re-MAG3-A7 accumulated in the G2/M
phase of the cell cycle (40.2% 6 1.46%), which was inhibited by
the presence of 1 mmol/L PTX (19.8% 6 8.12%) or 2 mmol/L
CAF (26.9% 6 6.21%). Conclusion: Cellular modulation of the
cell cycle with PTX and CAF radiosensitized LS180 colon cancer
cells exposed to 186Re radiation.
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Internal radiation therapy (IRT) using tumor-specific ra-
diopharmaceuticals, such as radiolabeled monoclonal anti-
bodies (mAbs), 131I-metaiodobenzylguanidine, and 90Y-anti-
somatostatin receptor ligands, has been examined for the
management of patients with malignant tumors. The re-
sponse rate of patients with refractory malignant lymphoma
to radioimmunotherapy is high (1,2). However, results in
other types of tumors are less favorable, and therefore the
sensitization of tumor cells to radiation with radionuclides
should be beneficial in enhancing the efficacy of IRT.
Cells with DNA damage induced by high-dose-rate radi-
ation are known to arrest at the G1 or G2 phase of the cell
cycle and repair the damage, resulting in augmentation of
their radioresistance (3). G1-phase arrest is mediated by the
p53 suppressor gene function (4,5), and the G2-phase arrest
is also affected by the p53 status to some extent (6,7).
However, G2-phase arrest can occur in the absence of
functional p53, as observed in many types of cancer cells
(8). Substantial evidence indicates that inhibition of the G2
arrest with methylxanthines (MTXs), such as pentoxifylline
(PTX) and caffeine (CAF), increases p53-independent apo-
ptosis after radiation (9–15). Inhibition of the G2 check-
point arrest also increases the death of cells with defective
apoptotic pathways through the induction of giant cells,
which would result from multiple rounds of DNA synthesis
in the absence of mitosis (9,10).
Low-dose-rate radiation may also induce the checkpoint
arrest of irradiated cells (16,17). However, most knowledge
about the radiosensitization effect of MTX is concerned
with high-dose-rate external-beam radiation, and little is
known about the effect of low-dose-rate radiation with
radionuclides emitting b-particles. Anderson et al. (16)
showed the radiosensitization effect of CAF in Chinese
hamster ovary cells irradiated with 131I, and Macklis et al.
(17) showed it in EL-4 lymphoma cells exposed to 90Y.
However, Macklis et al. indicated that Raji lymphoma cells
were not sensitized by CAF and that the radiosensitization
effect of CAF was not related to the cell cycle. Therefore,
Received Aug. 22, 2000; revision accepted Dec. 11, 2000.
For correspondence or reprints contact: Seigo Kinuya, MD, Department of
Nuclear Medicine, Kanazawa University School of Medicine, 13-1 Takara-
machi, Kanazawa, Ishikawa 920-8640, Japan.
596 THE JOURNAL OF NUCLEAR MEDICINE • Vol. 42 • No. 4 • April 2001
the cell cycle effect in cells exposed to low-dose-rate radi-
ation seems specific to the cell line. It is generally accepted
that the resistance of colorectal carcinomas to ionizing
radiation is associated with p53 mutation, and the inhibition
of G2 arrest with CAF reportedly increased the death of
colorectal cancer cells exposed to high-dose-rate g-radiation
(10). The reported response rate of colon carcinomas to
radioimmunotherapy was not high (18); therefore, the effect
of MTX on colon cancer cells exposed to b-radiation is
worth investigating.
186Re has abundant intermediate-energy b-emission (71%
of 1.07 MeV and 21% of 0.94 MeV). Its g-emission of 137
keV (9%) is suitable for external detection with gamma
cameras and produces a less nonspecific radiation dose than
does the high-energy g-emission of 131I (364 keV), which is
the most widely used nuclide in IRT. In this study, we
examined the effect of PTX and CAF on the survival of
human colon cancer cells lacking functional p53 protein
after exposure to a 186Re-labeled anti-colorectal cancer mAb
in vitro.
MATERIALS AND METHODS
Cell Culture and Radiolabeling
LS180 human colon cancer cells lacking functional p53 protein
(American Type Culture Collection, Rockville, MD) were main-
tained as a monolayer in a medium (Dulbecco’s modified Eagle
medium; Nissui Pharmaceutical Co., Ltd., Tokyo, Japan) with 10%
fetal calf serum at 37°C in a 5% CO2 atmosphere, harvested with
0.1% trypsin and 0.02% ethylenediaminetetraacetic acid, and in-
oculated into six-well culture plates. 186Re-perrhenate (186ReO42)
was produced by the 185Re(n,g) reaction (Japan Atomic Energy
Research Institute, Tokaimura, Japan), chelated with S-benzoyl-
mercaptoacetyltriglycine (S-benzoyl-MAG3) (a gift from Dr. Ya-
sushi Arano, Kyoto University), and conjugated to A7 (an IgG1
anti-colorectal carcinoma antibody) (19). Briefly, the mixture of
186ReO42, SnCl2, and S-benzoyl-MAG3 at the mol/L ratios of 2.3:1
for S-benzoyl-MAG3:Re and 8.0:1 for Sn21:Re was heated under
a N2 stream, resulting in 186Re-MAG3, which was conjugated to
A7 after esterification with 2,3,5,6-tetrafluorophenol (TFP) (Na-
calai Tesque, Kyoto, Japan). 186Re-MAG3-A7 was purified with a
PD-10 column (Pharmacia LKB Biotechnology, Uppsala, Swe-
den), and its immunoreactivity was assessed using LS180 cells
with an antigen excess.
Clonogenic Assay
LS180 cells were incubated in six-well culture plates with
0–925 kBq/mL 186Re-A7 in 2 mL medium for 24 h. PTX (Sigma,
St. Louis, MO) and CAF (Sigma) were added simultaneously to
the wells at concentrations of 0–5 mmol/L and 0–2 mmol/L,
respectively. The cells were washed with phosphate-buffered sa-
line (PBS) twice and maintained in fresh medium for 10 d. Cell
survival was determined by counting colonies fixed with 80%
methanol and stained with crystal violet. Colonies containing $50
cells were considered as survivors. The surviving fraction was
corrected by plating efficiency at each concentration of PTX and
CAF. A triplicate assay was performed in all experiments. The
data were fit to an exponential function to obtain a radioactivity
concentration, producing a surviving fraction of 0.5 (i.e., 50% cell
kill). An enhancement ratio (ER) at each concentration of PTX or
CAF was calculated as the ratio of 50% killing concentration in
control cells to that in cells treated with PTX or CAF.
Cell Cycle Analysis
The distribution of cells in the phases of the cell cycle was
analyzed with a flow cytometer (Cytoron Absolute; Ortho Diag-
nostic Systems, Raritan, NJ). Briefly, control cells and cells irra-
diated with 463 kBq/mL 186Re-MAG3-A7 in the presence or
absence of 1 mmol/L PTX or 2 mmol/L CAF were suspended at
2 3 106 cells/250 mL PBS, fixed with 250 mL 100% ethanol, and
stored at 4°C. The cells were washed and resuspended with 250 mL
ribonuclease A (500 U/mL; Sigma). They were then stained with
250 mL propidium iodide (50 mg/mL; Sigma). The DNA content
was analyzed with a flow cytometer, and the cellular distribution in
the cell cycle was determined. The results were analyzed by an
unpaired t test. In the analyses, the level of significance was set at
5%.
RESULTS
The incorporation of 186Re into S-benzoyl-MAG3 was
98%. The radiochemical yield of 186Re-MAG3-TFP produc-
tion was 89%, and 50% of 186Re-MAG3-TFP was conju-
gated to A7 mAb. The specific activity of purified 186Re-
MAG3-A7 was 90 MBq/mg, and its immunoreactivity was
63%.
Figure 1 and Table 1 summarize the effect of PTX and
CAF on the survival of LS180 colon cancer cells irradiated
with 186Re-MAG3-A7. The data of surviving curves were
well fit to an exponential function, showing R2 . 0.96 for
all assay conditions. The concentration of 50% cell kill was
FIGURE 1. Surviving fraction of LS180 colon cancer cells
exposed to 186Re-MAG3-A7 anti-colorectal mAb in presence of
PTX or CAF. F, Control cells; , PTX (0.5 mmol/L); , PTX
(2 mmol/L); h, CAF (1 mmol/L); n , CAF (5 mmol/L). Values are
mean 6 SD of triplicate assays.
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474 kBq/mL, and both PTX and CAF dose dependently
enhanced the cytotoxicity of 186Re-MAG3-A7.
Flow cytometry revealed that the cells exposed to 186Re-
MAG3-A7 accumulated in the G2/M phase of the cell cycle;
40.2% of the irradiated cells were found in the G2/M phase
compared with 11.3% of the control cells (P , 0.0001)
(Fig. 2). The presence of PTX or CAF inhibited the G2/
M-phase accumulation of irradiated cells (P , 0.01).
DISCUSSION
Once DNA damage is induced by ionizing radiation or
cytotoxic drugs, some of the damaged cells die through the
apoptotic pathway. Others survive by repairing the damage
during transient arrest at cell cycle checkpoints in the G1 or
G2 phase. G1-phase arrest is mediated by the p53 suppres-
sor gene function (4,5), and many tumor cells fail to arrest
at the G1 phase because of lack of functional p53. However,
G2-phase arrest can occur in the absence of functional p53,
as observed in many types of cells (8), and a correlation
between G2-phase arrest and radioresistance has been
shown (20,21). The inhibition of the G2 arrest with MTXs,
such as PTX and CAF, increases p53-independent apoptosis
after radiation (9–15), and the mechanism underlying the
inhibitory effect of CAF on the G2-phase arrest was re-
cently shown to be the inhibition of the Chk1 inhibitory
function on the phosphatase Cdc25c (22).
Although the positive effect of MTX in cells exposed to
high-dose-rate external-beam radiation has been well doc-
umented, only a few reports on low-dose-rate b-irradiation
are available, and the effect of cell cycle modulation on
b-irradiation is not fully understood. In this study, we
presented evidence of the radiosensitizing effect of PTX
and CAF in colon cancer cells exposed to 186Re radiation
and found a possible correlation between radiosensitization
TABLE 1




Control group‡ 474 —
PTX, 0.5 mmol/L 316 1.50
PTX, 2 mmol/L 217 2.18
CAF, 1 mmol/L 307 1.54
CAF, 5 mmol/L 180 2.64
*Concentration of radiocompound producing survival fraction of
0.5.
†Expressed as 50% kill dose of control/50% kill dose with PTX or
CAF.
‡Irradiated without PTX or CAF.
FIGURE 2. Representative histograms of
flow cytometry of LS180 colon cancer cells.
(A) Nonirradiated cells. (B) Cells irradiated
with 186Re-MAG3-A7 (463 kBq/mL for 24 h).
(C) Cells irradiated in presence of PTX
(1 mmol/L). (D) Cells irradiated in presence of
CAF (2 mmol/L). Mean 6 SD (n 5 3) of
percentage cells in G2/M phase of cell cycle
is indicated.
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and inhibition of the G2-phase arrest of irradiated cells.
Anderson et al. (16) similarly reported a radiosensitization
effect of CAF in Chinese hamster ovary cells irradiated
with 131I.
In contrast to these findings, the effectiveness of low-
dose-rate irradiation is usually explained by the G2-phase
accumulation of cells, because cells are radiosensitive in the
G2 phase (23). Ning and Knox (24) recently reported the
higher survival rate of CAF-treated HL60 leukemia cells
exposed to low-dose-rate g-radiation with a 137Cs source.
They concluded that the CAF-induced inhibition of the G2
arrest decreased the proportion of cells in the radiosensitive
G2 phase, resulting in a higher survival rate of CAF-treated
cells. On the other hand, the findings of Macklis et al. (17)
are inconsistent with this hypothesis. They found that EL-4
lymphoma cells, showing less G2 accumulation than Raji
lymphoma cells, were much more sensitive to low-dose-rate
b-radiation of 90Y than Raji cells, whereas these two cell
lines showed equal sensitivity to high-dose-rate g-radiation.
Deweese et al. (25) indicated that cell cycle modulation was
not a dominant determinant in five prostate cancer cell lines
exposed to low-dose-rate g-radiation. These inconsistent
reports suggest that the effect of cell cycle modulation on
the cytotoxicity of low-dose-rate radiation is likely specific
to the cell line (26).
Radiation-induced apoptosis plays an important role in
the responses of cells to irradiation, and MTX increases the
p53-independent apoptosis of cells after irradiation (9,10).
The expression level of Bcl-2, an anti-apoptotic oncogene,
may therefore correlate with the induction of apoptosis by
MTX (22). Other genes, such as p21, bax, RAF1, and p34,
may also be involved (27–31). Investigation with many cell
lines will be required to achieve a better understanding of
the effect of MTX in cells exposed to low-dose-rate radia-
tion with radiopharmaceuticals.
A limitation for the in vivo use of MTX is the difficulty
in achieving the concentration required for radiosensitiza-
tion through cell cycle modulation when administered sys-
temically (16). To obtain a sufficiently high concentration,
Tsuchiya et al. (32,33) intra-arterially infused CAF in pa-
tients with bone and soft-tissue sarcomas at a dose of 1.5
g/m2 for 3 consecutive days in combination with chemo-
therapeutic agents. They found a much better response rate
with this protocol than with conventional chemotherapy,
suggesting the possible applicability of MTX to enhance the
IRT effect. In addition, for the treatment of patients with
intraperitoneal dissemination, we may administer these
agents intraperitoneally, and it may be possible to obtain the
lesional concentrations required for the radiosensitization
effect of these agents in vivo. However, because IRT is a
systemic therapy and patients with early systemic metastatic
diseases would be the most suitable candidates for IRT (34),
systemic administration of MTX would be needed. There-
fore, the development of novel MTX derivatives of higher
potential or other types of agents acting as cell cycle mod-
ulators would be a priority.
To enhance the efficacy of IRT, improved targeting of
radiopharmaceuticals to tumors would be beneficial (35). It
has been shown that PTX may improve tumor perfusion and
oxygenation in vivo (36,37). Honess et al. (36) showed a
50%–70% increase of tumor perfusion by the administration
of PTX in a nontoxic dose range in an animal model, and
Song et al. (37) also showed an enhanced antitumor effect of
x-irradiation with increased tumor oxygenation in a model
administered with a similar nontoxic dose of PTX. These
reports indicate that this kind of agent would play a signif-
icant role in enhancing IRT efficacy by increasing tumor
accumulation of radiopharmaceuticals and improving tumor
oxygenation status.
CONCLUSION
PTX and CAF inhibited the G2-phase arrest of LS180
human colon cancer cells exposed to 186Re radiation and
decreased their survival. These results encourage further
investigation of the cell cycle checkpoint modulation of
tumor cells for the enhancement of IRT.
ACKNOWLEDGMENTS
The authors thank Dr. Yasushi Arano (currently at Chiba
University) for providing S-benzoyl-MAG3, Toshio Taka-
hashi and Dr. Toshiharu Yamaguchi (Kyoto Prefectural
University of Medicine) for A7 mAb, and John S. Gelblum
for assistance in preparing the manuscript. This study was
performed as a part of the Working Group on Radioactive
Rhenium supported by the Consultative Committee of
Research on Radioisotopes and the Subcommittee for Pro-
duction and Radiolabeling in the Japan Atomic Energy
Research Institute. This study was supported in part by
grants-in-aid from the Ministry of Education, Science,
Sports and Culture in Japan and from the Sagawa Cancer
Research Foundation.
REFERENCES
1. Kaminski MS, Zasadny KR, Francis IR, et al. Iodine-131-anti-B1 radioimmuno-
therapy for B-cell lymphoma. J Clin Oncol. 1996;14:1974–1981.
2. Press OW, Eary JF, Appelbaum FR, et al. Phase II trial of 131I-B1 (anti-CD20)
antibody therapy with autologous stem cell transplantation for relapsed B cell
lymphomas. Lancet. 1995;346:336–340.
3. Hartwell LH, Kastan MB. Cell cycle control and cancer. Science. 1994;266:
1821–1828.
4. O’Connor PM, Jackman J, Jondle D, Bhatia K, Magrath I, Kohn KW. Role of the
p53 tumor suppressor gene in cell cycle arrest and radiosensitivity of Burkitt’s
lymphoma cell lines. Cancer Res. 1993;53:4776–4780.
5. McIlwrath AJ, Vasey PA, Ross GM, Brown R. Cell cycle arrests and radiosen-
sitivity of human tumor cell lines: dependence on wild-type p53 for radiosensi-
tivity. Cancer Res. 1994;54:3718–3722.
6. Stewart N, Hicks GG, Paraskevas F, Mowat M. Evidence for a second cell cycle
block at G2/M by p53. Oncogene. 1995;10:109–115.
7. Guillouf C, Rosselli F, Krishnaraju K, Moustacchi E, Hoffman B, Liebermann
DA. p53 involvement in control of G2 exit of the cell cycle: role in DNA
damage-induced apoptosis. Oncogene. 1995;10:2263–2270.
8. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation
of p53 protein in the cellular response to DNA damage. Cancer Res. 1991;51:
6304–6311.
9. Bracey TS, Miller JC, Preece A, Paraskeva C. g-Radiation-induced apoptosis in
human colorectal adenoma and carcinoma cell lines can occur in the absence of
wild type p53. Oncogene. 1995;10:2391–2396.
RADIOSENSITIZATION WITH METHYLXANTHINE • Kinuya et al. 599
10. Bracey TS, Williams AC, Paraskeva C. Inhibition of radiation-induced G2 delay
potentiates cell death by apoptosis and/or the inhibition of giant cells in colorectal
tumor cells with disrupted p53 functions. Clin Cancer Res. 1997;3:1371–1381.
11. Rowley R. Reduction of radiation-induced G2 arrest by caffeine. Radiat Res.
1992;129:224–227.
12. Russell KJ, Wiens LW, Demers GW, Galloway DA, Plon SE, Groudine M.
Abrogation of the G2 checkpoint results in differential radiosensitization of G1
checkpoint-deficient and G1 checkpoint-competent cells. Cancer Res. 1995;55:
1639–1642.
13. Powell SN, DeFrank JS, Connell P, et al. Differential sensitivity of p53(2) and
p53(1) cells to caffeine-induced radiosensitization and override of G2 delay.
Cancer Res. 1995;55:1643–1648.
14. Russell KJ, Wiens LW, Demers GW, et al. Preferential radiosensitization of G1
checkpoint-deficiency cells by methylxanthines. Int J Radiat Oncol Biol Phys.
1996;36:1099–1106.
15. Li Y-X, Weber-Johnson K, Sun L-Q, Paschoud N, Mirimanoff R-O, Coucke PA.
Effect of pentoxifylline on radiation-induced G2-phase delay and radiosensitivity
of human colon and cervical cancer cells. Radiat Res. 1998;149:338–342.
16. Anderson LL, Lau CC, Gracely EJ, Berkowitz RS, Kassis AI. Enhancement of
131I-mediated cytotoxicity by caffeine. Gynecol Oncol. 1997;65:253–257.
17. Macklis RM, Beresford BA, Humm JL. Radiobiologic studies of low-dose-rate
90Y-lymphoma therapy. Cancer. 1994;73:966–973.
18. Divgi CR, Scott AM, Dantis L, et al. Phase I radioimmunotherapy trial with
iodine-131-CC49 in metastatic colon cancer. J Nucl Med. 1995;36:586–592.
19. Kinuya S, Yokoyama K, Tega H, et al. Rhenium-186-mercaptoacetyltriglycine
labeled monoclonal antibody for radioimmunotherapy: in vitro assessment, in
vivo kinetics and dosimetry in tumor-bearing nude mice. Jpn J Cancer Res.
1998;89:870–878.
20. Nagasawa H, Keng P, Harley R, Dahlberg W, Little JB. Relationship between
g-ray-induced G(2)/M delay and cellular radiosensitivity. Int J Radiat Biol.
1994;66:373–379.
21. Su L, Little JB. Prolonged cell cycle delay in radioresistant human cell lines
transfected with activated ras oncogene and/or simian virus 40 T-antigen. Radiat
Res. 1993;133:73–79.
22. Kumagai A, Guo Z, Emami KH, Wang SX, Dunphy WG. The Xenopus chk1
protein kinase mediates a caffeine-sensitive pathway of checkpoint control in
cell-free extracts. J Cell Biol. 1998;142:1559–1569.
23. Murtha AD. Radiobiology of low-dose-rate radiation relevant to radioimmuno-
therapy. Cancer Biother Radiopharm. 2000;15:7–14.
24. Ning S, Knox SJ. G2/M-phase arrest and death by apoptosis of HL60 cells
irradiated with exponentially decreasing low-dose-rate gamma radiation. Radiat
Res. 1999;151:659–669.
25. Deweese TL, Shipman JM, Dillehay LE, Nelson WG. Sensitivity of human
prostatic carcinoma cell lines to low dose rate radiation exposure. J Urol.
1998;159:591–598.
26. Musk SRR. Reduction of radiation-induced cell cycle blocks does not necessarily
lead to increased cell killing. Radiat Res. 1991;125:262–266.
27. Wouters BG, Denko NC, Giaccia AJ, Brown JM. A p53 and apoptotic indepen-
dent role for p21waf1 in tumour response to radiation therapy. Oncogene. 1999;
11:6540–6545.
28. Ofir R, Zhang LC, Kyne AP, Houtzager V, O’Connor L, Adams JM. Gamma-
radiation-induced growth arrest and apoptosis in p53-null lymphoma cells is
accompanied by modest transcriptional changes in many genes. DNA Cell Biol.
2000;19:29–37.
29. Bukholm IK, Nesland JM. Protein expression of p53, p21 (WAF1/CIP1), bcl-2,
Bax, cyclin D1 and pRb in human colon carcinomas. Virchows Arch. 2000;436:
224–228.
30. Warenius HM, Jones MD, Thompson CCM. Exit from G2 phase after 2 Gy
gamma irradiation is faster in radiosensitive human cells with high expression of
the RAF1 proto-oncogene. Radiat Res. 1996;146:485–493.
31. Yao S-L, Akhtar AJ, McKenna KA, et al. Selective radiosensitization of p53-
deficient cells by caffeine-mediated activation of p34cdc2 kinase. Nat Med. 1996;
2:1140–1143.
32. Tsuchiya H, Tomita K, Mori Y, et al. Caffeine-assisted chemotherapy and
minimized tumor excision for nonmetastatic osteosarcoma. Anticancer Res.
1998;18:657–666.
33. Tsuchiya H, Tomita K, Yamamoto N, Mori Y, Asada N. Caffeine-potentiated
chemotherapy and conservative surgery for high-grade soft-tissue sarcoma. An-
ticancer Res. 1998;18:3652–3656.
34. Juweid M, Sharkey RM, Behr T, et al. Radioimmunotherapy of patients with
small-volume tumors using iodine-131 labeled anti-CEA monoclonal antibody
NP-4 F(ab9)2. J Nucl Med. 1996;37:1504–1510.
35. Kinuya S, Yokoyama K, Kawashima A, et al. Pharmacologic intervention with
angiotensin II and kininase inhibitor enhanced efficacy of RIT in human colon
cancer xenografts. J Nucl Med. 2000;41:1244–1249.
36. Honess DJ, Dennis JF, Bleehen NM. Pentoxifylline: its pharmacokinetics and
ability to improve tumour perfusion and radiosensitivity in mice. Radiother
Oncol. 1993;28:208–218.
37. Song CW, Hasegawa T, Kwon HC, Lyons JC, Levitt SH. Increase in tumor
oxygenation and radiosensitivity caused by pentoxifylline. Radiat Res. 1992;130:
205–210.
600 THE JOURNAL OF NUCLEAR MEDICINE • Vol. 42 • No. 4 • April 2001
